3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Lung Neoplasms
44
Carcinoma, Hepatocellular
42
Small Cell Lung Carcinoma
28
Breast Neoplasms
18
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
16
Biliary Tract Neoplasms
15
Liver Neoplasms
13
Neoplasms
12
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
9
Carcinoma
9
Squamous Cell Carcinoma of Head and Neck
8
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Transitional Cell
6
Melanoma
5
Gallbladder Neoplasms
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Prostatic Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Mesothelioma
4
Interventions
Paclitaxel
7
Cyclophosphamide
6
Doxorubicin
5
pembrolizumab
3
Trastuzumab
3
Taxes
3
Specimen Handling
3
Carboplatin
3
pertuzumab
2
eribulin
2
Radiotherapy
2
Epirubicin
2
Docetaxel
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
ruxolitinib
1
pegfilgrastim
1
onvansertib
1
olaparib
1
neratinib
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Tamoxifen
1
Surgical Procedures, Operative
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
durvalumab
×
1 year
×
Clear all
NCT05795101
2025-09-19
TRUDI
Dana-Farber Cancer Institute
Phase 2
Recruiting
63 enrolled